Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892344 | 0.85 | NQO2 (0.53) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| SCHEMBL29713806 | 0.84 | DAO (0.56) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| SCHEMBL8230643 | 0.84 | DAO (0.56) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| SCHEMBL4424885 | 0.81 | NQO2 (0.57) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| Formaldehyde SCHEMBL28245545 | 0.78 | DAO (0.56) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| SCHEMBL599477 | 0.76 | CYP1A2 (0.87) | CYP1A2CYP2A6ALDH1A1MAPTPOLB | |
| SCHEMBL6705797 | 0.76 | CYP1A2 (0.87) | CYP1A2CYP2A6ALDH1A1MAPTPOLB | |
| SCHEMBL6446391 | 0.74 | ALDH1A1 (0.54) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| SCHEMBL15045468 | 0.74 | MAPT (0.43) | NQO2CYP1A2CYP2A6GAARXFP1 | |
| SCHEMBL15045465 | 0.74 | ACHE (0.45) | NQO2CYP1A2CYP2A6GAARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | NQO2 2390/4885CYP1A2 364/4885CYP2A6 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.